Skip to main content
Press release October 8, 2026

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven Ltd. (BHVN)

We couldn't retrieve the full text for this release. Read it on the company's site.

Read full release on company site